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Abstract
Objectives The goal of this paper is to investigate the
effects of activated complement C5a on vascular endo-
thelium during vessel formation.
Methods A human microvascular endothelial cell line
(HMEC-1) derived from post-capillary venules in skin was
used to measure DNA synthesis, proliferation and cell-
cycle progression. In vitro ring-shaped formation by the
cells was assessed by using type I collagen gel matrix and a
cell-migration assay using the Chemotaxicell chamber. A
Matrigel plug assay was performed to conﬁrm the effect of
C5a in vivo.
Results C5a progressed the cell cycle of HMEC-1 into
G2/M phases, and induced DNA synthesis and proliferation
in a dose-dependent manner. C5a efﬁciently induced
migration and ring-shaped structure formation both in vitro
and in vivo. Furthermore, a C5a receptor antagonist
(W-54011) suppressed all HMEC-1 activities including
proliferation and migration.
Conclusions Proliferation, migration, and ring-shaped
formation by HMEC-1 cells was induced by C5a. The
actions were efﬁciently inhibited by a speciﬁc antagonist
against C5a. Our results implicated C5a in vessel formation
and as a potent target for management of inﬂammatory
diseases.
Keywords C5a  Angiogenesis  Endothelial cell 
Inﬂammatory diseases  Activated complement
Introduction
Angiogenesis plays an important role in various inﬂam-
matory diseases. Multiple immune stimuli of both innate
immunity and acquired immunity activate complement
systems, often acting on mast cells via complement factors
such as C3a and C5a [1]. Mast cells enhance inﬂammation
initially by inducing the inﬁltration of polynuclear leuko-
cytes to the inﬂamed site, subsequently to macrophages and
lymphocytes [2]. Inﬂammation causes the endothelium to
produce angiogenesis-stimulating factors, such as ﬁbroblast
growth factor 2 (FGF-2), as well as stimulating the migra-
tion and proliferation of surrounding endothelial cells.
Moreover, enzymes are secreted to digest collagen in the
vascular basement membrane, and proliferating endothelial
cells form connections with neighbouring vessels. These
angiogenic steps play a signiﬁcant role in the development
and chronicity of inﬂammatory diseases [3–8].
The complement system comprises a series of enzymes
that induce inﬂammation in a cascade manner when acti-
vated by bacterial antigens and immune complexes.
Complement activation occurs via the classical, alternate,
or lectin-mediated pathways and activated complements
such as C3a and C5a help to eliminate foreign substances
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C5a is a 74-amino-acid peptide with a molecular weight
of 11.5 kDa produced during complement activation pro-
cesses [1]. C5a has multiple functions in various cells, such
as mast cell degranulation, monocyte migration, smooth
muscle contraction, blood vessel dilatation, recruitment of
immune cells and increased vascular permeability at
inﬂammatory sites [12]. C5a exerts its activities by binding
to the G-protein-coupled C5a receptor on the plasma
membrane of target cells. This cellular receptor for C5a
(CD88) is expressed in the liver, lung, kidney, and central
nervous system [13, 14], with a single human neutrophil
expressing 1–2 9 10
5 C5a receptors [1]. C5a activity has
been implicated in various diseases such as rheumatoid
arthritis, systemic lupus erythematosus, reperfusion injury,
Alzheimer’s disease and sepsis [15–21]. Indeed, activated
complement proteins including C5a have been identiﬁed
together with proinﬂammatory mediators such as cytokines
and proliferating neutrophils and macrophages in synovial
ﬂuid and synovial tissues of patients with rheumatoid
arthritis [22–25].
C5a is closely related to chronic inﬂammatory diseases
and possibly to angiogenesis [26]. The involvement of C5a
in arthritis was conﬁrmed in C5/C5aR-deﬁcient mice or by
using anti-C5/C5a antibodies; in both cases, the incidence
of collagen-induced arthritis was reduced [13, 27].
Although C5a receptors are widely expressed including by
vascular endothelial cells [9–11], the effects of activated
complement molecules remain unclear.
Materials and methods
Reagents
Recombinant human C5a was purchased from Sigma (St.
Louis, MO, USA). An orally active low molecular weight
C5aR-antagonist, W-54011, was synthesized by Mitsubishi
Tanabe Pharma Corporation according to the method
described previously [13]. W-54011 is species-selective,
with effects appearing only in humans, cynomolgus mon-
keys and gerbils [13, 14]. Type I collagen gel (Cellmatrix
Type I-A) was purchased from Nitta Zeratin Co. (Osaka,
Japan) and the Chemotaxicell chamber was obtained from
Kurabo (Tokyo, Japan).
Cell culture and treatment conditions
The human microvascular endothelial cell-1 (HMEC-1)
derived from subcutaneous postcapillary venules (ATCC,
Manassas, VA, USA) was grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM; Wako, Tokyo) supplemented
with 5% foetal bovine serum (FBS; Sigma) and penicillin–
streptomycin (Gibco BRL, Tokyo).
Flow cytometry
Hanks’ balanced salt solution containing 0.1% NaN3 and
1% FBS was used as the buffer in all ﬂow cytometry
experiments. Phycoerythrin (PE)-labelled anti-CD88
monoclonal antibody (PharMingen, Tokyo) was incubated
with HMEC-1 cells for 30 min at 4C. After three washes,
1 9 10
4-labelled HMEC-1 cells were analyzed by ﬂuo-
rescence-activated cell sorting (FACS) using the FACScan-
machine (Becton–Dickinson, Mountain View, CA, USA)
[25].
Measurement of proliferation, apoptosis and cell cycle
To measure cell proliferation, conﬂuent HMEC-1 cells
were detached with trypsin and ethylenediaminetetraacetic
acid (EDTA) solution, suspended in DMEM with 5% FBS,
and then seeded onto 96-well plates (0.32 cm
2/well; Nunc,
Kamstrup, Denmark). The cells were incubated until con-
ﬂuence. Cell growth was arrested for 24 h by replacing the
DMEM with 0.1% FBS, followed by incubation at 37C for
48 h with C5a or W-54011. [
3H]-thymidine was added to a
ﬁnal concentration of 3.7 9 10
5 Bq/mL for the last 18 h
and the cells were harvested using a semiautomatic cell
harvester (Abe Kagaku, Chiba, Japan). The amount of
radioactivity incorporated into the cellular DNA was
measured using a scintillation counter (Aloka LSC-
3500ETM, Tokyo) [5].
The cell cycle stage was assessed following propidium
iodine staining (PI; Sigma). HMEC-1 cells were seeded
onto six-well culture plates and incubated until conﬂuence.
Cell growth was arrested for 24 h as described previously,
washed with cold phosphate-buffered saline (PBS), and
then ﬁxed with 70% ethanol. The ﬁxed cells were incu-
bated with 10 lg/mL of ribonuclease A (RNase A) (Roche,
Japan) and 50 lg/mL PI for 10 min, and then the DNA
content was measured by FACScan.
Apoptotic cells were counted using the Annexin V
binding assay [28].
Cell viability was also measured using the Tetra Color
One cell proliferation assay (Seikagaku, Tokyo), according
to the instructions provided by the manufacturer. Brieﬂy,
HMEC-1 cells were seeded in 100 lL DMEM with 5%
FBS onto 96-multiwell plates and incubated until conﬂu-
ence. Cell growth was arrested for 24 h as described
previously. The plates were incubated at 37C for 48 h, and
then a tetrazolium (WST-8) mixture was added to a ﬁnal
volume of 110 lL/well. After 2 h incubation, absorbance
at 450 nm was measured using a microplate reader.
Quintuplicate cultures were used in all assays.
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Endothelial formation of ring-shaped structures was
assessed using type I collagen gel matrix. Eight volumes of
0.3% Cellmatrix type I-A solution (Nitta Gelatin) were
mixed with one volume each of reconstituted buffer (4.77 g
HEPES and 2.2 g NaHCO3 in 100 mL of 0.05 N NaOH)
and Roswell Park Memorial Institute (RPMI)-1640 med-
ium, and kept on ice. Then, 150 lL aliquots were placed in
each well of 12-well culture plates and immediately
incubated at 37C for 1 h to allow gel formation. After gel
solidiﬁcation, HMEC-1 cells (2 9 10
4 cells/0.3 mL) were
added to each well and incubated at 37C with W-54011,
C5a, and low-concentration FGF-2 (1 ng/mL). Finally,
each well was washed with PBS. The number of cells
forming ring-shaped structures was counted by inverted
microscopy. Results were expressed as the mean ± stan-
dard error of the mean (SEM) of 16 ﬁelds derived from
three wells [4]. Quintuplicate cultures were used in the
assay.
Cell migration assay
Cell migration activity was measured using a modiﬁed
Boyden Chemotaxicell chamber (Kurabo). Polycarbonate
ﬁlters with 8 lm pores (Kurabo) in the inner chamber were
preincubated for 1 h in 0.1% collagen type I (Nitta Gela-
tin). Cells (1 9 10
5) were suspended in DMEM with or
without W-54011 (0.1–10 nM), and placed in the upper
chambers of 24-well plates. FGF-2 (5 ng/mL) or various
concentrations of C5a (0.1–10 nM) with W-54011 was
added to the lower chambers. The apparatus was incubated
for 8 h at 37C, and then the upper chambers were disas-
sembled. Migrated cells were deﬁned as cells on the
reverse side of the membrane and also in the lower
chamber. Cells on the reverse side were removed with
trypsin and counted under a microscope. Triplicate cultures
were used in the assay.
Fig. 1 Expression of C5aR (CD88) on human microvascular endo-
thelial cells (HMEC-1). Flow cytometry results showing C5aR
expression (outlined area) on HMEC-1 cells without stimulation.
Dark areas indicate control
Fig. 2 Cell proliferation induced by C5a. [
3H]-thymidine incorpora-
tion was measured with a liquid scintillation counter 48 h after adding
the various concentrations of C5a, C5, or C3a to the HMEC-1
suspension. a C5a increased HMEC-1 proliferation in a dose-
dependent manner, whereas C5 (b) and C3a (c) did not induce
proliferation. d HMEC-1 was stimulated with either 10 nM C5a in the
presence of various concentrations of C5a receptor antagonist
W-54011 (closed column) or W-54011 alone (open column). The
addition of W-54011 inhibited cell proliferation induced by C5a
10 nM in a dose-dependent manner, whereas W-54011 alone had no
effect. Bars represent mean ± SEM (n = 5). **P\0.01 by
Dunnett’s multiple comparison test
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All animal experiments were performed according to the
guidelines for the care and use of animals approved by the
University of Occupational and Environmental Health,
Japan. Wild-type male C57BL/6 mice weighing 15–20 g
were obtained from Charles River Japan. Surgical
procedures were conducted under anesthesia (diethyl ether
was administered by inhalation for 3 min). Growth factor
reduced Matrigel (BD Biosciences, Bedford, MA, USA)
was prepared just before use under sterile conditions.
Matrigel solidiﬁes rapidly at 22–35C, and thus it was kept
on ice during each experiment. Matrigel in liquid form at
4C was mixed with the experimental solution (0.05 mL),
Fig. 3 Cell cycle progression induced by C5a. HMEC-1 cultures
were incubated with 10 nM C5a or the indicated concentrations of C5
and C3a. Cell cycle phases were determined by ﬂow cytometry with
PI staining enabling the determination of cells in the G0/G1 and S/G2/
M phases. a Cells in the S/G2/M phases advanced signiﬁcantly when
stimulated with 10 nM C5a for 48 h, and this effect was suppressed
by the addition of 10 nM W-54011. b C5a promoted cell cycle
progression in a dose-dependent manner, C5 (c) and C3a (d) had no
effect on the stage of cell cycle. e The indicated concentrations of
W-54011 were added in the presence of 10 nM C5a (closed bars)o r
without C5a (open bars). W-54011 suppressed the effect of C5a on
cell cycle whereas W-54011 alone had no effect. Bars represent
mean ± SEM (n = 5). *P\0.05 and **P\0.01 by Dunnett’s
multiple comparison test
Fig. 4 Cell viability was measured using the Tetra Color One assay.
The optical density of each well was measured at 450 nm. Phosphate-
buffered saline (PBS) alone was added to control samples. a C5a
increased the number of viable HMEC-1 cells at 1 and 10 nM, while
C5 (b) and C3a (c) had no such effects. d W-54011 inhibited the C5a-
augmented viable cell count (closed bars), but had no effect when
added alone (open bars). Bars represent mean ± SEM (n = 5).
**P\0.01 by Dunnett’s multiple comparison test
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cavity. The ﬁnal concentrations used in experiments were
1 lg/mL for FGF-2, 1 lM for C3a, and 100 nM for C5a.
All mice were injected at approximately the same sites.
Mice were sacriﬁced 14 days after implantation to remove
Matrigel plugs. The plugs were ﬁxed and processed into
the parafﬁn for immunohistochemical staining of sections
was performed using anti-CD31 antibodies (Abcam,
Cambridge, UK). Sections were counterstained with
hematoxylin–eosin (H&E). The areas containing inﬁltrat-
ing cells were identiﬁed by visually scanning the entire
section of each tissue sample [29–31].
Statistical analysis
Values were expressed as mean ± SEM. Differences
between groups were examined by the Bonferroni’s mul-
tiple comparison test. Differences between the control and
the other groups were examined by Dunnett’s multiple
comparison test. A P value\0.05 was considered statisti-
cally signiﬁcant.
Results
C5a induces proliferation of HMEC-1 cells
First, we used ﬂow cytometric analysis to conﬁrm that our
HMEC-1 endothelial cell line expressed the C5a receptor
(CD88) as expected (Fig. 1). Once established, the cells
were stimulated with different concentrations of C5a and
analyzed by [
3H]-thymidine incorporation to assess cell
proliferation. C5a induced a signiﬁcant proliferation of
HMEC-1 in a concentration-dependent manner, whereas
other complement factors, C5 and C3a, had no such effect
(Fig. 2a, b, c). The addition of W-54011, a speciﬁc C5a-
receptor antagonist, signiﬁcantly inhibited C5a-induced
proliferation in a dose-dependent manner, whereas
W-54011 alone had no effect (Fig. 2d).
C5a enhances cell cycle progression
We next investigated the effect of C5a on cell cycle pro-
gression in the HMEC-1 cells. Cells were incubated with
Fig. 5 Formation of ring-shaped structures in vitro. a Cells incubated
in the presence of phosphate-buffered saline (PBS) alone showed
minimal ring-shaped arrangements of the endothelial cells. Fibroblast
growth factor 2 (FGF-2; 1 ng/mL) induced slight ring-structure
formation, while 10 nM C5a dramatically increased the number of
ring-shape structures. This C5a-induced effect was inhibited by
W-54011. Original magniﬁcation: 940. b C5a increased the number
of ring-shaped structures formed by HMEC-1 in a dose-dependent
manner compared with FGF-2 alone. C5 and C3a did not induce the
formation of ring-shaped structures. c W-54011 inhibited ring-shaped
structure formation in a dose-dependent manner (closed bars)
whereas W-54011 alone had no effect (open bars). Bars represent
mean ± SEM (n = 5). **P\0.01 by Dunnett’s multiple comparison
test
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then analyzed by ﬂow cytometry (Fig. 3a). C5a signiﬁ-
cantly promoted cell cycle progression in a dose-dependent
manner at 48 h, whereas C5 and C3a had no effect (Fig. 3b,
c, d). Addition of W-54011 to the C5a incubation signiﬁ-
cantly inhibited cell cycle progression, while W-54011
alone had no effect (Fig. 3e).
C5a increases viable cell counts
The effect of C5a on cell viability was then evaluated using
the Tetra Color One assay with absorbance measured at
450 nm. C5a at both 1 and 10 nM increased signiﬁcantly
the HMEC-1 viable cell counts, whereas C5 and C3a did
not affect HMEC-1 viability, even at 10 nM (Fig. 4a, b, c).
The addition of 1 or 10 nM W-54011 suppressed the pro-
liferative effects of 10 nM C5a. Importantly, W-54011
alone had no effect on viable cell counts, conﬁrming its
low toxicity (Fig. 4d).
C5a increases ring-shaped structures of HMEC-1 cells
HMEC-1 cultures supplemented with 1 ng/mL FGF-2
contained a low proportion of ring-shaped structures.
However, C5a at both 1 and 10 nM markedly increased the
number of ring-shaped structures per well in a dose-
dependent manner. Again, C5 and C3a had no similar
effect (Fig. 5a, b). Furthermore, the formation of ring-
shaped structures induced by C5a was inhibited by
W-54011 dose-dependently (Fig. 5c).
C5a enhances cell migration
FGF-2 is a known inducer of endothelial cell migration
[32]. The migration by FGF-2 was conﬁrmed in this study
with the HMEC-1 line using the Chemotaxicell chamber
(Fig. 6a). C5a promoted HMEC-1 migration in a dose-
dependent manner, an effect that was inhibited in the
presence of W-54011 (Fig. 6a, b).
C5a induces inﬁltration and microvascular-like
structure of endothelial cells in vivo
To conﬁrm the in vitro results in an in vivo model, Matrigel
plugs supplemented with PBS (controls), FGF-2, C5a, or
C3a were implanted subcutaneously into mice. Signiﬁcant
cell inﬁltration into the plugs was observed in the presence
of FGF-2, whereas PBS-control plugs showed minimal cell
inﬁltration (Fig. 7a, e). As expected, C5a, but not C3a, also
induced cell inﬁltration (Fig. 7b, f and d, h). Furthermore,
both C5a and FGF-2 induced inﬁltration of adipocytes into
the plugs, suggesting early stage angiogenesis. To conﬁrm
the endothelial cell inﬁltration, the Matrigel plugs were
sectioned and then stained with anti-CD31 antibody.
CD31
? endothelial cells were scarce in plugs supple-
mented with PBS and C3a. However, the addition of FGF-2
or C5a induced accumulation of CD31
? endothelial cells in
the plugs and subsequent formation of microvascular-like
structure (Fig. 7e–h). Thus, the in vivo results mirrored
those observed in vitro.
Discussion
C5a plays a role in the immune response including inﬂam-
mation. Angiogenesis also occurs at inﬂammatory sites;
however,the roleofC5a inangiogenesisremains unclear.In
particular, its effect on the proliferation or migration of
vascular endothelial cells is unknown, despite ﬁndings that
C5a induces genes encoding ICAM-1 and E-selectin in
vascularendothelium[33].ThepresentstudyfoundthatC5a
causes an increase in the ratio of the S/G2/M cell-cycle
phases in cultured vascular endothelial cells. Furthermore,
the increase in both [
3H]-thymidine uptake and viable cell
count indicated a critical role for C5a in the proliferation of
these cells. Finally, these effects were all suppressed by the
addition of a C5a receptor antagonist (W-54011).
C5a has a chemotactic effect on various immune cells
including monocytes [34, 35], although a similar activity
toward endothelial cells is unknown. In this study, C5a
Fig. 6 Analysis of HMEC-1 migration. HMEC-1 cells migrated to
the reverse side of the ﬁlters were removed with trypsin and counted.
a FGF-2 (5 ng/ml) was used as a positive control for inducing
HMEC-1 migration (open column). C5a increased the migration of
HMEC-1 cells in a dose-dependent manner (closed column), while
this induced migration was inhibited by W-54011. b In a dose-
dependent manner. Bars represent mean ± SEM (n = 3).
a **P\0.01 by Bonferroni’s multiple comparison test,
b **P\0.01 by Dunnett’s multiple comparison test
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Chemotaxicell chamber and increased CD31
? endothelial
cell inﬁltration into abdominally sited Matrigel plugs in
vivo, with the cells forming ring-shaped structures in both
cases. These migration-inducing activities of C5a were also
inhibited by W-54011, indicating that C5a exerts chemo-
tactic effects on vascular endothelial cells and has the
potential to stimulate angiogenesis.
It is noteworthy that C5a also induced the inﬁltration of
adipocytes into the Matrigel plugs in vivo. Applications of
angiogenic growth factors in models of adipogenesis and
angiogenesis have been described previously [36]. Neo-
vascularization was induced by recruitment of adipocyte
precursor cells when Matrigel was implanted subdermally,
supplemented with the angiogenic factor FGF-2 [36]. In
ourexperiments,the Matrigel plugcontainingC5aorFGF-2
showed increased accumulation of CD31
? endothelial cells
and microvascular-like structure formation with inﬁltration
of adipocytes. These results suggested that C5a could
participate in the vascularization and accumulation of
adipocytes around inﬂamed vessels.
C5a is associated with various diseases [3–8], but efforts
to develop antagonists have not yet been successful. W-
54011 was recently identiﬁed as an orally active, potent,
nonpeptide, and competitive C5a receptor antagonist of
low molecular weight [13, 14]. In our study, W-54011
inhibited proliferation, migration, and ring-shaped structure
formation of HMEC-1 cells induced by C5a, as well as the
processes of vessel formation involving endothelial cells.
The involvement of C5a in disease was proven in
experiments with C5/C5aR-deﬁcient mice or anti-C5/C5a
antibodies. As C5aR antagonists have become available,
their therapeutic potential has been veriﬁed in inﬂamma-
tion models [13, 14, 27]. Our present results indicate that
the C5aR antagonist W-54011 possesses not only anti-
inﬂammatory effects but also inhibitory effects on neo-
vascularization, suggesting a potential application for
W-54011 as a novel therapeutic agent for the management
of various inﬂammatory diseases such as rheumatoid
arthritis [13, 14].
In conclusion, the C5a-induced stimulation of vascular
endothelial cells affects angiogenesis-related processes
including cell proliferation, migration, and ring-shaped
structure formation. Furthermore, these effects were
inhibited by the addition of W-54011, a speciﬁc C5a-
receptor-antagonist. Thus, C5a receptor antagonists are of
potential clinical use for treatment of inﬂammatory dis-
eases such as rheumatoid arthritis, asthma, psoriasis, graft
rejection, and inﬂammatory bowel diseases.
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